Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant VEGF (Bevacizumab Biosimilar) antibody

Reactivity: Human FACS, in vivo Host: Mouse Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN7200653
  • Target See all VEGF (Bevacizumab Biosimilar) products
    VEGF (Bevacizumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    • 1
    • 1
    • 1
    • 1
    Mouse
    Clonality
    • 3
    • 2
    Monoclonal
    Conjugate
    • 5
    This VEGF (Bevacizumab Biosimilar) antibody is un-conjugated
    Application
    • 4
    • 3
    • 3
    • 3
    • 3
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Purpose
    Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody
    Specificity
    The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.
    Characteristics
    Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
    Purification
    Protein A affinity column
    Purity
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterility
    0.2 μm filtered
    Endotoxin Level
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.
    Isotype
    IgG1 kappa
  • Application Notes
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Preservative
    Without preservative
    Handling Advice
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Expiry Date
    12 months
  • Target
    VEGF (Bevacizumab Biosimilar)
    Abstract
    VEGF (Bevacizumab Biosimilar) Products
    Synonyms
    MVCD1 antibody, VEGF antibody, VPF antibody, vascular endothelial growth factor A antibody, VEGFA antibody
    Target Type
    Biosimilar
    Background
    Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.

    Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
You are here:
Support